Opus Genetics to Present Clinical Data, Manufacturing Strategy at Key Ophthalmology Conferences

Event summary

  • Opus Genetics leadership will present at the Collaborative Community on Ophthalmic Innovation (CCOI) in Hong Kong, February 3-4, 2026.
  • The company will engage with the ophthalmology community at the Asia-Pacific Academy of Ophthalmology (APAO) Congress in Hong Kong, February 5-8, 2026.
  • Chief Technology Officer Chris Ernst will discuss scalable viral vector manufacturing models at Advanced Therapies Week Conference in San Diego, February 11, 2026.
  • Preliminary results from a Phase 1b/2a clinical study of OPGx-BEST1 will be presented at The Macula Society Annual Meeting in San Diego, February 27, 2026.

The big picture

Opus Genetics' conference participation highlights the ongoing race to develop gene therapies for inherited retinal diseases, a market with significant unmet need but also substantial technical and regulatory hurdles. The company's focus on both clinical data and manufacturing scalability indicates a dual strategy of demonstrating efficacy and preparing for potential commercialization. The company’s pipeline includes seven AAV-based programs, suggesting a broad commitment to gene therapy solutions.

What we're watching

Clinical Progress
The presentation of preliminary data for OPGx-BEST1 at The Macula Society will be critical in assessing the viability of the program and its potential to address BEST1-related retinal degeneration, a relatively niche but unmet need.
Manufacturing Scale
The focus on scalable viral vector manufacturing suggests Opus Genetics is anticipating increased demand for its therapies, but the success of this strategy will hinge on cost-effectiveness and regulatory approval.
Geographic Expansion
Participation in the APAO Congress signals an intent to expand Opus Genetics’ presence in the Asia-Pacific region, requiring careful navigation of local regulatory landscapes and market access challenges.